RxDoctor Payments Data

William Roach, MD

Family Medicine · Visalia, CANPI 1538125497

Payments from drug & device makers

$601in general payments, 2019–2025

Across 26 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$83
  • Haemonetics Corporation$80
  • Lilly USA, LLC$74
  • Stemline Therapeutics Inc.$69
  • Johnson & Johnson$51
  • Dexcom, Inc.$48
  • plus $197 from 7 others

What the payments were for

  • Food & beverage$601100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$601 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$2,132
Medicare patients
17
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$133,902
OzempicSemaglutide83$97,783
EliquisApixaban71$50,138
XareltoRivaroxaban25$27,293
TrulicityDulaglutide14$22,385
JanuviaSitagliptin Phosphate17$20,390
FarxigaDapagliflozin Propanediol20$20,338
Xultophy 100-3.6Insulin Degludec/Liraglutide17$20,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$17,399
EntrestoSacubitril/Valsartan15$15,161
LinzessLinaclotide14$14,567
MyrbetriqMirabegron19$11,409
ByettaExenatide12$9,611
Breo ElliptaFluticasone/Vilanterol22$9,389
MovantikNaloxegol Oxalate22$8,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$83$142,351134 claims
Novo NordiskOzempic, Xultophy 100-3.6$18$118,027100 claims
AstraZenecaFarxiga, Byetta$34$29,95032 claims
Johnson & JohnsonXarelto$51$27,29325 claims
GSKTrelegy Ellipta, Breo Ellipta$36$26,78752 claims
Lilly USA, LLCTrulicity$74$22,38514 claims
AbbVieLinzess, Armour Thyroid$38$15,73226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →